PRESS RELEASES

Available as PDF, Word or Pages

Immutep receives approx AUD 1 million in Research and Development tax incentive

Immutep is pleased to announce that it has received an AUD 986,286 cash rebate from the Australian Federal Government’s Research and Development tax incentive program

14/11/2022

Orgenesis achieves revenue of USD 8.0 million for the third quarter of 2022
  • Secures up to USD 50 million of funding from Metalmark Capital Partners expected to accelerate rollout of point-of-care services

  • Reduces operating expenses by 49 percent to achieve nearly breakeven income from operation for the third quarter of 2022

11/11/2022

Immutep granted new patents in Japan and South Korea for first-in-class LAG-3 candidate, eftilagimod alpha in chemo-immunotherapy combination

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce the grant of two new patents

10/11/2022

Immutep announces promising initial clinical data from INSIGHT-003 at SITC 2022 
  • First activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7 percent response rate and 90.9 percent disease control rate in first-line NSCLC patients 

  • The triple combination therapy has been well tolerated and appears to be safe

10/11/2022

Immutep announces compelling clinical results from Phase II trial utilizing its first-in-class soluble LAG-3 protein, eftilagimod alpha, in first-line NSCLC at SITC 2022 Annual Meeting.

Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces compelling new clinical data from the TACTI-002 all-comer PD-L1 Phase II trial

10/11/2022

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe

The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD)

10/11/2022

BioSenic provides update on its autoimmune disease platform based on ATO (arsenic trioxide)
  • The autoimmune disease platform has completed a successful phase IIb trial targeting cGVHD (chronic Graft vs Host Disease), with a demonstrated efficacy of more than 75 percent

  • Phase III is under preparation with expected accelerated examination by FDA

  • Other indications should follow with wider market potential, including lupus and systemic sclerosis

08/11/2022

Orgenesis secures up to USD 50 Million subsidiary-level investment from Metalmark Capital to accelerate growth of Point-of-Care services

Metalmark Capital Partners, a leading private equity firm with extensive expertise in the healthcare sector, today announced an investment partnership whereby Metalmark has agreed to make a growth investment of up to USD 50 million in Orgenesis

07/10/2022

Bone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation of Medsenic valued at EUR 40 million

    •    New company’s pipeline enriched with serious inflammatory indications in addition to its original cell therapy asset

    •    New Chairman, Board Members and Management appointed 24,463,421 ALLOB subscription rights granted to all existing shareholders

13/10/2022

TrakCel and ZS partner to advance cell and gene therapy orchestration through AI and technology

Enhanced data analytics to provide CGT sector with technological support as advanced as the development of CGTs 

13/10/2022

Bone Therapeutics to regain worldwide rights to ALLOB
  • Bone Therapeutics received a unilateral termination notice from Pregene

  • Link Health expressed continued interest in ALLOB

  • Bone Therapeutics to continue negotiating rights for ALLOB with Link Health and other partners

19/09/2022

Immutep announces abstracts accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Initial data from INSIGHT-003 trial treating patients with various solid tumours with triple combination therapy of efti, anti-PD-1 therapy, and chemotherapy to be discussed at SITC

05/10/2022

Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer 
  • Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancer

  • Based on the encouraging Phase II clinical data for PD-L1 all-comers presented at ASCO 2022 

  • Marks the second Fast Track designation issued by the FDA for eftilagimod alpha, offering the potential for expedited development and review

04/10/2022

Immutep receives AUD 2.7 million research and development tax incentive from French government

The “Crédit d’Impôt Recherche” (CIR), meaning “Research Tax Credit”, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30 percent of their eligible expenditure.

Immutep qualifies to receive the CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory in France.

23/09/2022

Terumo Blood and Cell Technologies launches Quantum Flex bioreactor

Terumo Blood and Cell Technologies launches Quantum Flex bioreactor platform, one of the first systems that enables cell therapy commercialization from process development through manufacturing

 

  • Next-generation platform makes hollow-fiber perfusion technology commercially relevant and delivers advanced software to support cGMP

19/09/2022

Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, provides a clinical development update for its first-in-class LAG-3 antigen-presenting cell (APC) activator product candidate, eftilagimod alpha ("efti").

14/09/2022

Minoryx‘s marketing authorization application for its lead candidate leriglitazone validated by EMA

Late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders, today announces that it has filed a Marketing Authorization Application (MAA) for its lead candidate leriglitazone to the European Medicines Agency (EMA)

14/09/2022

Ori Biotech and CTMC partner to accelerate novel cell therapy delivery

Ori is a leader in cell and gene therapy (CGT) manufacturing technologies, and the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience Inc and MD Anderson Cancer Center, today announce a collaborative partnership to develop industrial manufacturing processes for cell therapies.

13/09/2022

Immutep appoints LAG-3 pioneer, Frédéric Triebel to Board

Biotechnology company developing LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the appointment of its Chief Scientific Officer and Chief Medical Officer, Professor Frédéric Triebel, M.D. Ph.D. as Executive Director. Prof. Triebel will join the Immutep Board with immediate effect.

13/09/2022

ISCT issues response to US federal judge ruling on FDA regulation of cell and gene therapies

ISCT, the global society of clinicians, researchers, regulators, technologists, and industry partners dedicated to the translation of cell and gene therapy (CGT) into safe and effective therapies to improve patients' lives.

12/09/2022

ISCT addresses manufacturing standardization, a critical issue constraining the CGT development pipeline

ISCT, the global society of clinicians, researchers, regulators, technologists, and industry partners dedicated to the translation of cell and gene therapy (CGT) into safe and effective therapies to improve patients' lives, today announces the publication of its key insights report from the 4th Annual ISCT Commercialization Signature Series event

08/09/2022

Bone Therapeutics reports half year 2022 results
  • Bone Therapeutics acquires majority participation in Medsenic to derisk and broaden its therapeutic portfolio[1]

  • Preparation of the Medsenic Phase III clinical trial with oral formulation following positive results from Phase II arsenic trioxide in the first-line treatment of cGvHD (chronic GvH)

  • Bone Therapeutics ALLOB’s Phase IIb interim results expected in H1 2023

07/09/2022

Immutep announces investigator-initiated Phase II trial evaluating LAG-3 candidate eftilagimod alpha (efti) in soft tissue sarcoma

Immutep is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland

06/09/2022